Inactivation of viruses by β-propiolactone in human cyro poor plasma and IgG concentrates

Abstract

Virus inactivation by cold treatment with β-propiolactone (BPL) was investigated in human cyro poor plasma and purified IgG concentrates spiked with relevant human viruses or appropriate animal model viruses.The samples were treated with 0.1 or 0.25% BPL for 300 or 480 min, respectively. Residual infectivity was determined by standard microtitration assays on tissue culture cells. The inactivation of all viruses tested was more effective in IgG than in plasma. IgG: R1=4–5.5 log10for vesicular stomatitis virus (VSV). Semliki Forest virus (SFV), bovine virus diarrhoea virus (BVDV), murine encephalomyelitis virus (MEV), feline calicivirus (FVC), suid parvovirus (PPV), simian virus 40 (SV40); R1=2–4 log10for suid herpesvirus type 1 (SHV-1), bovine herpesvirus type 1 (BHV-1), human immunodeficiency virus type 2 (HIV-2), simian immunodeficiency virus (SIVagm3). Plasma: R1=3–5 log10for VSV, SFV, BVDV, SHV-1, MEV:R1=0–3 log10for HIV-1, SIVagm3BHV-1, FCV, PPV, SV40. After addition of SIVagm3, HIV-2, and PPV to plasma or lgG, spontaneous inactivation without further addition of BPL was observed.These results demonstrate that treatment with BPL has a limited capacity to inactivate viruses. Different inactivation kinetics were observed in plasma and IgG concentrates. Therefore, virus inactivation by BPL must be tested for individual blood products independently and should not be extrapolated from other model systems.